Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Wen

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Plos One|December 10, 2016
Gene-Targeted Mice with the Human Troponin T R141W Mutation Develop Dilated Cardiomyopathy with Calcium DesensitizationMohun Ramratnam, Guy Salama, Ravi K Sharma, et al.
BMC Geriatrics|April 16, 2022
Relevance of presenting risks of frailty, sarcopaenia and osteopaenia to outcomes from aneurysmal subarachnoid haemorrhageJia Xu Lim, Yuan Guang Lim, Aravin Kumar, et al.
BMJ Open|September 22, 2021
Predictors of incident SARS-CoV-2 infections in an international prospective cohort studyAnthony Lin, Eric Vittinghoff, Jeffrey Olgin, et al.
Open Heart|January 21, 2022
Prospective arrhythmia surveillance after a COVID-19 diagnosisThomas A Dewland, Isaac R Whitman, Sithu Win, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2008
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitorsYihan Wang, William C Shakespeare, Wei-Sheng Huang, et al.
Journal of Medicinal Chemistry|July 4, 2009
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluationWei-Sheng Huang, Xiaotian Zhu, Yihan Wang, et al.
Bioorganic & Medicinal Chemistry Letters|May 13, 2011
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutantMathew Thomas, Wei-Sheng Huang, David Wen, et al.
Journal of Medicinal Chemistry|June 2, 2010
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutantWei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Plos One|December 10, 2016
Gene-Targeted Mice with the Human Troponin T R141W Mutation Develop Dilated Cardiomyopathy with Calcium DesensitizationMohun Ramratnam, Guy Salama, Ravi K Sharma, et al.
BMC Geriatrics|April 16, 2022
Relevance of presenting risks of frailty, sarcopaenia and osteopaenia to outcomes from aneurysmal subarachnoid haemorrhageJia Xu Lim, Yuan Guang Lim, Aravin Kumar, et al.
BMJ Open|September 22, 2021
Predictors of incident SARS-CoV-2 infections in an international prospective cohort studyAnthony Lin, Eric Vittinghoff, Jeffrey Olgin, et al.
Open Heart|January 21, 2022
Prospective arrhythmia surveillance after a COVID-19 diagnosisThomas A Dewland, Isaac R Whitman, Sithu Win, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2008
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitorsYihan Wang, William C Shakespeare, Wei-Sheng Huang, et al.
Journal of Medicinal Chemistry|July 4, 2009
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluationWei-Sheng Huang, Xiaotian Zhu, Yihan Wang, et al.
Bioorganic & Medicinal Chemistry Letters|May 13, 2011
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutantMathew Thomas, Wei-Sheng Huang, David Wen, et al.
Journal of Medicinal Chemistry|June 2, 2010
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutantWei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, et al.
Pageof 3